01
Clinical trials
Trial design, endpoints, enrollment, and what the results can genuinely support.
Independent reporting on regenerative medicine
The clearest signal in stem cell science.
Evidence-led briefings on trials, therapies, regulation, and the business of cellular medicine—written for people who need the facts without the hype.
Source-linked Plain English No miracle claims
THE EVIDENCE SIGNALLive framework
Every briefing separates what is known from what is merely possible.
01ClaimWhat is being said?
02EvidenceWhat supports it?
03ContextWhat is still unknown?
What we track
One field. Four essential lenses.
The science is only useful when its clinical, regulatory, and commercial context is visible too.
02
Cell therapies
A practical map of platforms, indications, manufacturing, and translational progress.
03
Safety & policy
Regulatory decisions, patient protections, and the line between care and marketing.
04
Market signals
Funding, partnerships, and commercial moves—viewed through the strength of the science.
Our standard
Evidence before excitement.
Stem cell science deserves optimism—and scrutiny. We read past the press release and show you where each claim sits on the path from laboratory finding to patient care.
Primary sources firstStudies, trial records, regulators, and direct company filings.
Uncertainty stays visibleLimitations and unanswered questions are part of the story.
Clear medical boundariesEducation and reporting—not personal medical advice.